Skip to main content
    K

    Krystal Biotech Inc (KRYS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $297.90
    -7.33 (-2.40%)

    Market Cap: $9.05B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Krystal Biotech Inc (KRYS) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Krystal Biotech (KRYS) is expected to report earnings on Feb 15, 2027. In the quarter ended Sep 30, 2026, Krystal Biotech reported EPS of $2.05, above the $1.84 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    51%(19/37)
    Avg Surprise
    +9.27%
    Streak
    5 Q

    Upcoming Estimates

    Reports Feb 15, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.09
    Range$1.75 - $2.54
    14 analysts
    Revenue Consensus
    $137.50M
    Range$128.46M - $144.10M
    13 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.08
    Range$1.80 - $2.52
    4 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$2.23-6.6%
    60d ago$2.23-6.6%
    30d ago$2.23-6.6%
    7d ago$2.16-3.4%
    Current$2.08
    Revenue Consensus
    $139.42M
    Range$134.40M - $144.10M
    5 analysts

    Next Report

    KRYS has an expected report date of Feb 15, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 22.9% above the $1.70 reported for the quarter ended Dec 31, 2025.

    KRYS Earnings Call

    The latest KRYS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, KRYS beat 19, missed 16 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $127.34M, up 30.2% from $97.80M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.05$1.84$1.49 - $3.04+11.41%Beat-22.9%100 up, 1 downNov 2, 2026$127.34M
    Jun 30, 2026$1.79$1.70$1.28 - $3.64+5.29%Beat+38.8%80 up, 1 downAug 3, 2026$119.22M
    Mar 31, 2026$1.83$1.42$1.28 - $1.61+28.87%Beat+52.5%70 up, 1 downMay 4, 2026$116.36M
    Dec 31, 2025$1.70$1.58$1.36 - $1.92+7.59%Beat+11.1%30 up, 0 downFeb 17, 2026$107.11M
    Sep 30, 2025$2.66$1.12$0.99 - $1.24+137.50%Beat+192.3%41 up, 0 downNov 3, 2025$97.80M
    Jun 30, 2025$1.29$1.44$1.11 - $2.11-10.42%Miss+38.7%41 up, 1 downAug 4, 2025$96.04M
    Mar 31, 2025$1.20$1.52$1.47 - $1.57-21.05%Miss+3900.0%21 up, 0 downMay 6, 2025$88.18M
    Dec 31, 2024$1.53$1.85$1.15 - $3.21-17.39%Miss+59.4%31 up, 0 downFeb 19, 2025$91.14M
    Sep 30, 2024$0.91$0.90$0.63 - $1.16+1.11%BeatN/A80 up, 0 downNov 4, 2024$83.84M
    Jun 30, 2024$0.93$0.99N/A-6.06%MissN/A61 up, 1 downAug 5, 2024$70.28M
    Mar 31, 2024$0.03$0.15-$0.10 - $0.31-80.00%MissN/A72 up, 0 downMay 6, 2024$45.25M
    Dec 31, 2023$0.96-$0.25-$0.95 - -$0.01+484.00%BeatN/A80 up, 1 downFeb 26, 2024$42.14M
    Sep 30, 2023-$0.67-$0.67-$1.38 - $2.510.00%In lineN/A71 up, 0 downNov 6, 2023$8.56M
    Jun 30, 2023-$1.25-$0.74-$1.37 - $2.24-68.92%MissN/A60 up, 0 downAug 7, 2023N/A
    Mar 31, 2023-$1.76-$1.44-$2.04 - -$1.17-22.22%MissN/A70 up, 0 downMay 8, 2023N/A
    Dec 31, 2022-$1.25-$0.56N/A-123.21%MissN/A60 up, 0 downFeb 27, 2023N/A
    Sep 30, 2022-$1.17-$1.26-$1.62 - -$0.93+7.14%BeatN/A70 up, 0 downNov 7, 2022N/A
    Jun 30, 2022-$1.10-$1.00-$1.04 - -$0.90-10.00%MissN/A60 up, 0 downAug 8, 2022N/A
    Mar 31, 2022-$0.99-$1.05-$1.65 - -$0.88+5.71%BeatN/A70 up, 0 downMay 9, 2022N/A
    Dec 31, 2021-$0.95-$0.73-$0.82 - -$0.62-30.14%MissN/A8N/AFeb 28, 2022N/A
    Sep 30, 2021-$0.70-$0.74-$0.88 - -$0.61+5.41%BeatN/A74 up, 0 downNov 8, 2021N/A
    Jun 30, 2021-$0.74-$0.78-$1.07 - -$0.61+5.13%BeatN/A8N/AAug 9, 2021N/A
    Mar 31, 2021-$0.74-$0.56-$0.70 - -$0.43-32.14%MissN/A10N/AMay 10, 2021N/A
    Dec 31, 2020-$0.53-$0.59-$0.71 - -$0.50+10.17%BeatN/A9N/AMar 1, 2021N/A
    Sep 30, 2020-$0.49-$0.46-$0.60 - -$0.37-6.52%MissN/A9N/ANov 9, 2020N/A
    Jun 30, 2020-$0.37-$0.39-$0.66 - -$0.37+5.13%BeatN/A8N/AAug 10, 2020N/A
    Mar 31, 2020-$0.31-$0.44-$0.55 - -$0.35+29.55%BeatN/A7N/AMay 4, 2020N/A
    Dec 31, 2019-$0.31-$0.33-$0.45 - -$0.26+6.06%BeatN/A7N/AMar 10, 2020N/A
    Sep 30, 2019-$0.25-$0.40-$0.43 - -$0.32+37.50%BeatN/A7N/ANov 4, 2019N/A
    Jun 30, 2019-$0.37-$0.31-$0.35 - -$0.29-19.35%MissN/A7N/AAug 5, 2019N/A
    Mar 31, 2019-$0.29-$0.33-$0.39 - -$0.29+12.12%BeatN/A5N/AMay 7, 2019N/A
    Dec 31, 2018-$0.27-$0.23-$0.28 - -$0.20-17.39%MissN/A5N/AMar 12, 2019$1.03M
    Sep 30, 2018-$0.26-$0.26-$0.30 - -$0.230.00%In lineN/A4N/ANov 5, 2018N/A
    Jun 30, 2018-$0.22-$0.34-$0.42 - -$0.26+35.29%BeatN/A2N/AAug 6, 2018N/A
    Mar 31, 2018-$0.21-$0.48-$0.48 - -$0.48+56.25%BeatN/A1N/AMay 7, 2018N/A
    Dec 31, 2017-$0.26-$0.23N/A-13.04%MissN/AN/AN/AMar 12, 2018N/A
    Sep 30, 2017-$1.26-$0.74N/A-70.27%MissN/AN/AN/ANov 13, 2017N/A
    Jun 30, 2017-$0.06N/AN/AN/AN/AN/AN/AN/ASep 20, 2017N/A
    Last 38 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $6.85, up 101.5% from the year before. It was -$1.58 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$6.85+101.5%
    Dec 31, 2024$3.40N/A
    Dec 31, 2023-$2.72N/A
    Dec 31, 2022-$4.51N/A
    Dec 31, 2021-$3.13N/A
    Dec 31, 2020-$1.70N/A
    Dec 31, 2019-$1.22N/A
    Dec 31, 2018-$0.96N/A
    Dec 31, 2017-$1.58N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,700 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,73118
    2026Q2Jun 30, 20265,46914
    2026Q1Mar 31, 20265,92615
    2025Q4Dec 31, 20255,31911
    2025Q3Sep 30, 20255,32613
    2025Q2Jun 30, 20256,34016
    2025Q1Mar 31, 20257,70415
    2024Q4Dec 31, 20246,46415

    2026Q3 Earnings Call

    Opening remarks

    Stephane Paquette Senior Vice President of Corporate Development Good morning, and thank you all for joining today's call. Earlier today, we released our financial results for the third quarter of 2026. The press release is available on our website at www.krystalbio.com. We also filed our earnings 8-K and 10-Q with the SEC earlier today. Joining me today are Krish S. Krishnan, Chairman and Chief Executive Officer; Suma Krishnan, President of Research and Development; Laurent Goux, Executive Vice President and General Manager for Europe; Christine Wilson, Senior Vice President and Head of U.S. Commercial; and Kathryn A. Romano, Chief Accounting Officer. This conference call and our responses to questions may contain forward-looking statements. You are cautioned not to rely on these forward-looking statements, which are based on current expectations using the information available as of the date of this call and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties, and other factors can be found in our SEC filings. With that, I will turn the call over to Krish.

    Krish S. Krishnan Chairman and Chief Executive Officer Good morning, and thank you for joining us. Q3 was another strong quarter for Krystal. We had $127.3 million in VYJUVEK revenue, an increase of 30% from the same period last year, reported diluted earnings of $2.05 per share, and ended September with $1.2 billion in cash and investments. Those results reflect a business that is growing, profitable, and generating the resources to advance our pipeline. They also reflect the work our teams have done to build Krystal into a global company with commercial operations, manufacturing capabilities, and clinical development programs that we own and control. Today, we have generated approximately $1.1 billion in VYJUVEK revenues since launch, and that is an important milestone for a medicine developed here at Krystal. Behind that number are so many patients receiving treatment, physicians incorporating a new paradigm of genetic medicines into their practices, and families getting access to a medicine that addresses the underlying cause of DEB. In the U.S., demand continues to grow, as does the prescribing physician base. Internationally, we continue to translate physician interest into patient starts across Germany, France, and Japan. The pricing secured for VYJUVEK in Japan, Germany, and Italy reflects recognition of the meaningful benefits that VYJUVEK provides patients and families. I am proud of our team's thoughtful work to demonstrate that value and establish a strong foundation for patient access internationally. We will continue to build on this progress in ensuing pricing discussions across additional markets, and Laurent will discuss those markets in more detail. We also made meaningful progress in development.

    Frequently Asked Questions About KRYS

    When is Krystal Biotech's next earnings date?

    Krystal Biotech's next earnings report is expected for Feb 15, 2027.

    Did KRYS beat earnings estimates last quarter?

    Yes. Krystal Biotech reported EPS of $2.05 for the quarter ended Sep 30, 2026, above the $1.84 estimate, a 11.41% surprise.

    What EPS do analysts expect from KRYS next quarter?

    The consensus EPS estimate for Krystal Biotech for the quarter ending Dec 31, 2026 is $2.09 from 14 analysts, with estimates from $1.75 to $2.54.

    How often does KRYS beat earnings estimates?

    Krystal Biotech beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +17.73%.